Data from key phase III clinical trials incorporating neoadjuvant, adjuvant, and perioperative immunotherapy strategies outline the current treatment landscape for early-stage NSCLC without epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) alterations, as summarized in Table 1. Here, ALK is linked to non-small cell lung carcinoma.